Malaysia to prioritise high-risk patients under National Liver Health Initiative 2026–2030

KUALA LUMPUR, 11 OCTOBER 2026 —

KUALA LUMPUR, Oct 11 — Malaysia will prioritise targeted screening for individuals at higher risk of liver disease under its National Liver Health Initiative 2026–2030, a strategic shift designed to enhance early detection of liver cancer and strengthen coordination among healthcare providers.

The decision reflects a calculated approach to resource allocation, with the minister arguing that a targeted strategy is more financially prudent than population-wide screening. By concentrating efforts on groups with established risk factors, the initiative aims to identify patients with advanced liver fibrosis before their conditions progress to severe complications such as cirrhosis and liver cancer.

This method is intended to direct limited healthcare resources toward individuals most likely to benefit from timely intervention, thereby improving overall system efficiency.

Dr Dzulkefly outlined the strategy during the launch of the National Liver Health Initiative Roadmap 2026–2030 at Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia, on Sunday. The roadmap addresses not only screening but also the fragmentation currently present in the management of liver disease across the country. The government intends to establish a coordinated patient care pathway that covers the full spectrum of care, from prevention and screening to diagnosis, treatment, and long-term monitoring.

A central component of this integrated care model is the connection between primary healthcare facilities, hospitals, specialist services, and tertiary medical centres. This arrangement is designed to ensure that patients can move between different levels of care without unnecessary interruptions, a critical factor in managing chronic conditions. The Health Minister placed particular emphasis on individuals diagnosed with hepatitis B and C, noting that these patients often require continued clinical assessment and monitoring.

He stated that every diagnosed patient must have a clear route to appropriate treatment and follow-up care to prevent them from being lost to the system after an initial diagnosis.

To achieve this continuity of care, the initiative proposes the implementation of a coordinated patient-tracking system and improved information-sharing mechanisms between healthcare facilities. These measures are essential for reducing the risk of patients falling through the cracks of the healthcare system, a common challenge in managing complex, long-term diseases.

By streamlining communication and data flow, the government aims to create a seamless experience for patients while ensuring that clinical teams have access to the most up-to-date information for decision-making.

The implementation of the initiative is structured around a proposed 12-month framework, which Dr Dzulkefly presented as a possible sequence rather than a confirmed nationwide rollout timetable. The initial stage involves a comprehensive assessment of the existing situation, including disease prevalence, current diagnosis rates, treatment arrangements, and identified gaps in healthcare services. This baseline assessment is crucial for identifying specific areas where improvements are needed and for tailoring subsequent interventions to local realities.

Following the assessment, the next stage will involve the development of standardised testing and referral protocols to support more consistent management of patients across different facilities. Once these protocols are established, integrated services will be piloted at selected healthcare facilities. Patient outcomes from these pilot programmes will be carefully evaluated before the approach is considered for wider implementation.

This phased approach allows for adjustments based on real-world data, ensuring that the final system is both effective and sustainable.

The urgency of the initiative is underscored by the clinical reality that liver cancer often develops without obvious symptoms. Dr Dzulkefly warned that this lack of early warning signs results in some patients receiving their diagnosis only after the disease has reached an advanced stage. He noted that delayed detection can substantially reduce treatment options and significantly lower survival prospects.

The minister highlighted the stark contrast in outcomes based on the timing of diagnosis, citing five-year survival rates of approximately 70 per cent when liver cancer is detected early.

In comparison, he cited survival rates of less than five per cent for patients diagnosed at stage four. These figures illustrate the critical importance of detecting the disease before it progresses to its most severe forms. While individual outcomes depend on clinical circumstances and available treatments, the data supports the government’s strategy of prioritising early detection.

The roadmap therefore places equal emphasis on improved access to diagnosis, treatment, and continued care, recognising that early detection is only one part of a comprehensive strategy to improve patient outcomes.

Beyond domestic healthcare improvements, Dr Dzulkefly expressed an ambition for Malaysia to promote liver health as a global public health priority at a future World Health Assembly. He stated that this aspiration would build on Malaysia’s earlier efforts to advance lung health discussions on the international stage.

While the proposed international initiative remains an aspiration, with no specific World Health Assembly session or formal proposal announced, it signals the government’s intent to leverage its domestic progress to influence global health policy.

For Malaysia, the immediate priority remains the development of a more integrated liver healthcare system that identifies high-risk patients earlier and ensures they receive appropriate care. The National Liver Health Initiative 2026–2030 is intended to strengthen this process through targeted screening, coordinated referrals, and long-term patient monitoring.

The ultimate objective, as stated by the Health Minister, is to improve patient outcomes by ensuring liver disease is detected and treated before preventable complications become more severe, thereby reducing the burden on the healthcare system and improving quality of life for affected individuals.

Related: Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia · Datuk Seri Dr Dzulkefly Ahmad · Kuala Lumpur